Phase2, Single Group, Open Clinical Trial to Evaluate the Efficacy and Safety of Roflumilast in Symptomatic Bronchiectasis Patients

There is currently no effective treatment of bronchiectasis other than treating its complications such as infection, bleeding, etc. Roflumilast is a newly developed anti-inflammatory drug that has proven to be effective in stable COPD. We hypothesized that Roflumilast might be effective in symptomatic bronchiectasis patients

Inclusion Criteria:

• Bronchiectasis on CT
• chronic (>3 months) cough or sputum

Exclusion Criteria:

• needs hospitalization
• life expectancy of less than six months
• pregnancy or breast feeding
• history of acute respiratory infection within 4 weeks
• history of taking antibiotics within 4 weeks
• active hemoptysis
• %predicted FEV < 30%
• severe liver disease (Child Pugh Class B or C)